Selexipag denied as not medically necessary by Humana?

Humana's specific coverage criteria for selexipag are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Humana Denies Selexipag on Medical-Necessity Grounds

Selexipag is an oral prostacyclin receptor agonist approved for pulmonary arterial hypertension (PAH). Humana's medical-necessity denials typically occur when the submitted documentation does not clearly establish that the patient meets the insurer's criteria for PAH treatment with a prostacyclin-pathway agent — often because functional class, prior therapy history, or hemodynamic confirmation is insufficiently documented at the time of the request.

## Why This Denial Is Appealable

PAH is a serious, progressive, and potentially fatal condition. When a prescriber has determined that selexipag is medically necessary, that clinical judgment deserves full scrutiny — not a rubber-stamp denial. Federal law gives you the right to challenge this decision through a structured appeal process.

## Your Federal Appeal Rights

• ACA §2719 / External Review: Most commercial and marketplace plans must offer independent external review. You generally have approximately four months from the denial notice to request external review. An independent organization — not Humana — then makes a binding determination.
• ERISA §503 (employer-sponsored plans): Requires a full-and-fair review with a clear written explanation of the denial rationale and the specific criteria applied. You may request the complete claim file, including the clinical guidelines used.
• Expedited appeal: If your prescriber certifies that waiting for standard review timelines would seriously jeopardize your health, request an expedited internal appeal and/or expedited external review simultaneously.

## Appeal Timeline

1. File your internal appeal promptly — Humana must acknowledge receipt and resolve it within the timeframe specified in your plan documents (typically 30–60 days for standard, 72 hours for expedited). 2. If the internal appeal is upheld, immediately request external review — do not wait. 3. Track all submission dates and confirmation numbers in writing.

## Documentation to Gather

• Diagnosis confirmation: Right-heart catheterization report establishing PAH diagnosis and hemodynamic data; echocardiography and imaging reports.
• Functional classification: Physician note explicitly stating current WHO/NYHA functional class per current chart findings.
• Prior treatment history: Dates, agents, doses, and documented response or failure for all prior PAH therapies tried.
• Clinical severity: Six-minute walk distance trends, BNP/NT-proBNP laboratory values, and any evidence of disease progression.
• Prescriber letter: A detailed medical-necessity letter from the treating pulmonologist or PAH specialist explaining why selexipag is the appropriate next step for this specific patient.

## Criteria-Mapping Structure

Obtain Humana's published medical policy for PAH and prostacyclin-pathway agents (request it directly from Humana or locate it on their provider portal). Then, for each requirement listed in that policy, document the specific chart fact that satisfies it. Separately, confirm that your use aligns with the FDA-approved prescribing information for selexipag. Present this as a side-by-side table in your appeal letter so the reviewer cannot overlook any element.